Difference between revisions of "Scleroderma"
Jump to navigation
Jump to search
m (→General) |
|||
| Line 4: | Line 4: | ||
Clinical: | Clinical: | ||
*Anti-centromere antibody (ACA) +ve. | *Anti-centromere antibody (ACA) +ve. | ||
**Common in ''limited systemic scleroderma'', [[AKA]] CREST | **Common in ''limited systemic scleroderma'', [[AKA]] CREST syndrome. | ||
*Scl-70 (topoisomerase I) +ve. | *Scl-70 (topoisomerase I) +ve. | ||
**Common in ''diffuse scleroderma''. | **Common in ''diffuse scleroderma''. | ||
CREST syndrome: | |||
*Calcinosis. | |||
*Raynaud's phenomenon. | |||
*[[esophagus|Esophageal]] dysmotility. | |||
*Sclerodactyly. | |||
*Telangiectasia. | |||
==Associated pathology== | ==Associated pathology== | ||
Revision as of 22:49, 3 December 2011
Scleroderma is a disease that keeps rheumatologists busy.
General
Clinical:
- Anti-centromere antibody (ACA) +ve.
- Common in limited systemic scleroderma, AKA CREST syndrome.
- Scl-70 (topoisomerase I) +ve.
- Common in diffuse scleroderma.
CREST syndrome:
- Calcinosis.
- Raynaud's phenomenon.
- Esophageal dysmotility.
- Sclerodactyly.
- Telangiectasia.